Prof Paul Neeson
Honorary Conjoint Professorial Fellow
The Sir Peter MacCallum Department of Oncology
256 Scholarly works
18 Projects
HIGHLIGHTS
2026
Journal article
Recurrent intra-tumour heterogeneity is a hallmark of metastatic prostate cancer
DOI: 10.1038/s41467-026-74334-z2026
Journal article
Tumor-resident T cells and dendritic cells form an in situ archetype during immunotherapy response in melanoma
DOI: 10.1038/s41467-026-74076-y2026
Journal article
Germline BRCA1 pathogenic variants and T cell dysfunction
DOI: 10.1016/j.iotech.2026.1016012026
Journal article
Pembrolizumab as first therapy for elderly or comorbid patients with classical Hodgkin lymphoma: Results of the phase 2 PLIMATH trial.
DOI: 10.1111/bjh.707772022
Research grants (ARC, NHMRC, MRFF)
Targeting Cold Tumours With Triple Therapy
2017
Research grants (other domestic)
Novel Approaches for Overcoming Resistance to Therapies for Advanced Melanoma
2017
Research Grant
Combination of Radionuclide 177lu-Psma Therapy With Pembrolizumab in Patients With Metastatic Castration-Resistant Prostate Cancer (Mcrpc)
RECENT SCHOLARLY WORKS
2026
Journal article
Breast implant associated anaplastic large cell lymphoma is a heterogeneous T cell disease with active pro-tumour cross-talk and immune suppression.
DOI: 10.1038/s41375-026-03049-32026
Journal article
Single-fraction or multi-fraction stereotactic ablative body radiotherapy followed by atezolizumab in advanced triple-negative breast cancer: a randomized phase II trial
DOI: 10.1038/s41467-026-75660-y2026
Journal article
Dynamic immune profiling predicts response to radiation plus anti-PD-1 therapy in oligometastatic renal cell carcinoma.
DOI: 10.1038/s41467-026-74255-x2026
Journal article
Metastasis-directed Therapy With or Without Pembrolizumab for Oligometastatic Clear Cell Renal Cell Carcinoma: Pooled Analysis of Two Prospective Single-arm Phase 2 Trials
DOI: 10.1016/j.eururo.2026.03.0242026
Journal article
ENHANCING CHIMERIC ANTIGEN RECEPTOR (CAR) T CELL THERAPY FOR PAEDIATRIC SARCOMA THROUGH CAR T ENGINEERING AND TUMOUR MICROENVIRONMENT REWIRING
DOI: 10.1016/j.jcyt.2026.1022252026
Journal article
[177Lu]Lu-PSMA-617 in combination with pembrolizumab for treatment of metastatic castration resistant prostate cancer (PRINCE): a single-arm, phase 1b/2 study
DOI: 10.1016/S1470-2045(26)00017-3
RECENT PROJECTS
2024
Research grants (other domestic)
New Frontiers for CAR T Cell Therapy in Breast Cancer
2026
Research grants (other domestic)
Generating Early-Phenotype CAR-T for Treatment of Solid Tumours in Pet Dogs